Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?

Research output: Contribution to journalArticle

Abstract

ONTARGET has established the efficacy of the angiotensin receptor blocker (ARB) telmisartan to slow disease progression and delay or prevent morbid events in patients with atherosclerosis. Although the study failed to confirm additive efficacy of telmisartan and the angiotensin-converting-enzyme (ACE) inhibitor ramipril, caution should be exercised in assuming that the mean response in a clinical trial applies to individual patients who might benefit from combination therapy. Physicians should also recognize that the design of the study, in which full doses of the ACE inhibitor and the ARB were administered, might not replicate clinical practice, where one drug is usually added to the other.

Original languageEnglish (US)
Pages (from-to)526-527
Number of pages2
JournalNature Clinical Practice Cardiovascular Medicine
Volume5
Issue number9
DOIs
StatePublished - Jul 30 2008

Fingerprint

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Ramipril
Disease Progression
Atherosclerosis
Clinical Trials
Physicians
Pharmaceutical Preparations
telmisartan
Therapeutics

Cite this

Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events? / Cohn, Jay N.

In: Nature Clinical Practice Cardiovascular Medicine, Vol. 5, No. 9, 30.07.2008, p. 526-527.

Research output: Contribution to journalArticle

@article{e053d6b74e794b5c95e94bee489a8d36,
title = "Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?",
abstract = "ONTARGET has established the efficacy of the angiotensin receptor blocker (ARB) telmisartan to slow disease progression and delay or prevent morbid events in patients with atherosclerosis. Although the study failed to confirm additive efficacy of telmisartan and the angiotensin-converting-enzyme (ACE) inhibitor ramipril, caution should be exercised in assuming that the mean response in a clinical trial applies to individual patients who might benefit from combination therapy. Physicians should also recognize that the design of the study, in which full doses of the ACE inhibitor and the ARB were administered, might not replicate clinical practice, where one drug is usually added to the other.",
author = "Cohn, {Jay N}",
year = "2008",
month = "7",
day = "30",
doi = "10.1038/ncpcardio1303",
language = "English (US)",
volume = "5",
pages = "526--527",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?

AU - Cohn, Jay N

PY - 2008/7/30

Y1 - 2008/7/30

N2 - ONTARGET has established the efficacy of the angiotensin receptor blocker (ARB) telmisartan to slow disease progression and delay or prevent morbid events in patients with atherosclerosis. Although the study failed to confirm additive efficacy of telmisartan and the angiotensin-converting-enzyme (ACE) inhibitor ramipril, caution should be exercised in assuming that the mean response in a clinical trial applies to individual patients who might benefit from combination therapy. Physicians should also recognize that the design of the study, in which full doses of the ACE inhibitor and the ARB were administered, might not replicate clinical practice, where one drug is usually added to the other.

AB - ONTARGET has established the efficacy of the angiotensin receptor blocker (ARB) telmisartan to slow disease progression and delay or prevent morbid events in patients with atherosclerosis. Although the study failed to confirm additive efficacy of telmisartan and the angiotensin-converting-enzyme (ACE) inhibitor ramipril, caution should be exercised in assuming that the mean response in a clinical trial applies to individual patients who might benefit from combination therapy. Physicians should also recognize that the design of the study, in which full doses of the ACE inhibitor and the ARB were administered, might not replicate clinical practice, where one drug is usually added to the other.

UR - http://www.scopus.com/inward/record.url?scp=50649097447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649097447&partnerID=8YFLogxK

U2 - 10.1038/ncpcardio1303

DO - 10.1038/ncpcardio1303

M3 - Article

VL - 5

SP - 526

EP - 527

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - 9

ER -